DLBCL R/R-->
L MIND study versus real world Tafa ( anti CD 19 Ab)+ Len
- In the real world experience, PFS was less than 2 months and OS 6 months. ORR 30%
-LMIND- PFS 13 months, ORR 55%
-L-MIND phase II study demonstrated durable responses in this population. The regimen consists of tafasitamab 12 mg/kg intravenously in combination with lenalidomide 25 mg orally (days 1–21 of each 28-day cycle) for up to 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity
Now tafa approved in FL -inMIND study for 2nd line FL ( approved June 2025)- PFS 22 months, versus 14 months control arm
No comments:
Post a Comment